The protein product of the novH oncogene, a member of the CCN family, is structurally related to the insulin-like growth factor (IGF) binding proteins (IGFBPs). We have characterized aspects of structure, function, and distribution of this protein, which, as IGFBPrelated protein 3 (IGFBP-rP3), is a proposed member of the IGFBP Superfamily. Affinity cross-linking experiments performed with baculovirus synthesized recombinant human IGFBP-rP3 established that rhIGFBP-rP3 binds IGF-I, IGF-II, and insulin with low affinity. Specificity of binding was shown by competitive cross-linking experiments; binding to IGF-I and -II was also demonstrated by nondenaturing Western ligand blots. Northern blot analysis indicated the presence of IGFBP-rP3 messenger RNA (mRNA) in a broad range of human tissues. Western immunoblotting studies, using a polyclonal rabbit anti-rhIGFBP-rP3 antibody, demonstrated that IGFBP-rP3 protein is synthesized in vitro by several breast and prostate cancer cell lines: Hs578T, PC3, P69, and LNCaP cells. Western immunoblotting studies of human biological fluids identified that IGFBP-rP3 was present in normal serum, pregnancy serum, serum from patients with growth hormone receptor deficiency, cerebrospinal fluid, amniotic fluid, peritoneal fluid, and follicular fluid, while IGFBP-rP3 fragments were identified in cerebrospinal fluid, amniotic fluid, and prepubertal and pubertal urine samples. Our studies demonstrate that IGFBP-rP3 exhibits IGF binding, albeit at low affinity, and IGFBPrP3 thus merits inclusion in the IGFBP Superfamily. The low affinity IGF binding suggests that IGFBP-rP3 may act primarily independently of the IGFs. The synthesis of IGFBP-rP3 by several malignant cell lines and its presence in human biological fluids suggest that this protein possesses other interesting roles, potentially in cell growth regulation. (J Clin Endocrinol Metab 84: 1096 -1103, 1999 
protein is synthesized in vitro by several breast and prostate cancer cell lines: Hs578T, PC3, P69, and LNCaP cells. Western immunoblotting studies of human biological fluids identified that IGFBP-rP3 was present in normal serum, pregnancy serum, serum from patients with growth hormone receptor deficiency, cerebrospinal fluid, amniotic fluid, peritoneal fluid, and follicular fluid, while IGFBP-rP3 fragments were identified in cerebrospinal fluid, amniotic fluid, and prepubertal and pubertal urine samples. Our studies demonstrate that IGFBP-rP3 exhibits IGF binding, albeit at low affinity, and IGFBPrP3 thus merits inclusion in the IGFBP Superfamily. The low affinity IGF binding suggests that IGFBP-rP3 may act primarily independently of the IGFs. The synthesis of IGFBP-rP3 by several malignant cell lines and its presence in human biological fluids suggest that this protein possesses other interesting roles, potentially in cell growth regulation. (J Clin Endocrinol Metab 84: 1096 -1103, 1999) T HE nephroblastoma overexpressed (nov) oncogene, which is normally suppressed in adult kidney cells, was first described in chickens with myeloblastosis-associated, virus-induced nephroblastoma (1) . The human nov cDNA (novH), expressed as a 2.2 kb messenger RNA (mRNA), was then cloned and sequenced (2, 3) . The detection of novH expression in Wilm's tumor suggests a role in cell growth regulation, particularly as the level of novH expression was found to show an inverse correlation with the expression of the tumor suppressor gene WT1 (2) .
The nov oncogene has been grouped within the CCN family, which is comprised of connective tissue growth factor (CTGF), Cyr61 and NovH; and these proteins share an overall similarity of 46% (4) . This group of cysteine-rich proteins is thought to regulate cell proliferation, differentiation, embryogenesis, and wound healing (5) . Within the N-terminus, NovH has an approximately 46% amino acid sequence similarity to the IGFBPs and contains 11 of the 12 N-terminus cysteines conserved amongst the IGFBPs (6) , including the GCGCCXXC motif (2) , suggesting that it is a potential member of the IGFBP Superfamily. The IGFBP Superfamily encompasses the 6 traditional IGFBPs -1 to -6 and a group of structurally similar proteins, which have recently acquired the nomenclature of IGFBP-related proteins (IGFBP-rPs) (7) .
We have recently demonstrated IGF binding properties for IGFBP-rP1 (also referred to as mac25/TAF/PSF) and for IGFBP-rP2 (also referred to as CTGF) (8 -10) . The structural data would suggest that the remaining members of the CCN family, in addition to CTGF/IGFBP-rP2, most likely also possess IGF binding capabilities. The studies presented in this paper investigate these properties for NovH/IGFBP-rP3. No studies to date have investigated the IGF binding properties of Cyr61.
In the present study, we report the expression of recombinant human NovH/IGFBP-rP3 in a baculovirus system and demonstrate that 38 kDa IGFBP-rP3 specifically binds IGF-I, IGF-II, and insulin. These studies confirm the merits of inclusion of NovH within the IGFBP Superfamily, along with the appropriateness of its new label, IGFBP-rP3. Our further investigation of the presence of IGFBP-rP3 in biological fluids and in conditioned media of several malignant and nonmalignant cell lines outlines the distribution of this protein, postulated to be involved in cell regulation.
Co. (Indianapolis, IN) . High-performance liquid chromatography-purified IGFBP-1 from human amniotic fluid was kindly provided by Dr. D. R. Powell (Baylor College of Medicine, Houston, TX); rhIGFBP-2, -4, -5, and -6 were purchased from Austral Biologicals (San Ramon, CA); rhIGFBP-3, a nonglycosylated 29-kDa core protein expressed in Escherichia coli was a generous gift from Celtrix, Inc. (Santa Clara, CA). rhIGFBP-rP1 and -rP2 were expressed in a baculovirus system, as previously described (8, 11) . Iodination of IGF-I and IGF-II was performed by a modification of the chloramine-T technique, to a specific activity of 350 -500 mCi/mg (12) .
125 I-labeled insulin was purchased from Amersham Life Science (Arlington, IL).
125 I-labeled C-peptide of insulin was a gift from Diagnostic Systems Laboratories (Webster, TX). Human multiple-tissue Northern blots were purchased from CLONTECH (Palo Alto, CA).
Cloning of the IGFBP-rP3/novH cDNA and expression of recombinant human IGFBP-rP3
PCR used on the IGFBP-rP3/novH cDNA, which was subcloned from a Hs578T cDNA library (a human mammary carcinoma cell line), to add the eight amino acid FLAG epitopes (DYKDDDDK) and a new stop codon to the 3Ј end, using the following primers: 5Ј primer CGC GAA TTC GCC ATG CAG AGT GTG CAG AGC ACG and the 3Ј primer CCG CCG CTC GAG TTA CTT GTC ATC GTC GTC CTT GTA GTC CAT TTT CCC TCT GGT AGT. The IGFBP-rP3 PCR product was digested with EcoRI and XhoI, ligated into the baculovirus expression vector pFAST-BAC1 (Life Technologies Inc., Grand Island, NY), and sequenced to confirm that the PCR-generated product contained no mutations (2) . The rhIGFBP-rP3 construct was transfected into insect SF9 cells, and positive viral recombinants were isolated according to the manufacturer's protocol. Western immunoblots (WIB) were performed with the FLAGsequence specific anti-FLAG-M2 antibody (Eastman Kodak Co., Rochester, NY) to confirm the expression of rhIGFBP-rP3 (NovH) protein (9) .
Protein purification
Large scale protein purification of rhIGFBP-rP3 was performed by infecting 10 8 HIGH Five insect cells with the IGFBP-rP3 recombinant virus particles at a multiplicity of infection of 3, and incubated at 27 C for three days. The media from the incubated cells were collected and centrifuged. The supernatant was incubated with anti-FLAG M2 antibody affinity beads at 4 C for 2 h, the beads were washed three times with 5 mL HBSS (20 mm Hepes pH 7.8, 150 mm NaCl), and the IGFBP-rP3 protein was eluted with five 1-mL washes with HBSS containing 0.33 mg/mL FLAG peptide. The purified protein was electrophoresed on a 12% SDS-PAGE gel, which was stained with Coomassie blue or transferred to a nitrocellulose membrane for WIB with the anti-FLAG M2 antibody.
Eluted fractions from an anti-FLAG M2 antibody affinity column were pooled, electrophoresed on a 12% SDS-PAGE gel, silver stained, and quantitated by densitometric analysis; comparison was made with known amounts of BSA. Purified IGFBP-rP3 (10 g) was subjected to 12% SDS-PAGE and electroblotted to polyvinylidene difluoride (PVDF) membrane in 10% methanol 10 mm 3-[cyclohexylamino]-1-propanesulfonic acid pH 11 transfer buffer, and then stained with 0.2% Ponceau-S solution. Determination of the NH 2 -terminal sequence (Biotechnology Laboratory in the Institute of Molecular Biology, University of Oregon) was performed by Edman degradation, using a 470A gas-phase protein Sequencer equipped with a 120A phenylthiohydantoin analyzer (PE Applied Biosystems, Foster City, CA).
WIBs with anti-FLAG-M2 antibody
Samples were electrophoresed on nonreducing 12% SDS-PAGE, transferred to nitrocellulose membrane (13) , blocked in 5% nonfat dry milk: TBS-T (20 mm Tris-Cl pH 7.6, 150 mm NaCl, 0.1% Tween 20) at room temperature for 1 h. The membranes were washed three times in TBS-T, before incubation in the primary antibody, anti-FLAG-M2 antibody at a 1:4000 dilution in TBS-T, overnight at 4 C. The membranes were washed in TBS-T three times and then incubated with the secondary antibody, horseradish peroxidase-linked anti-mouse IgG (Amersham, Arlington Heights, IL) at a 1:4000 dilution, for 2 h at room temperature. The membranes were then washed twice in TBS-T for 15 min, and immunodetection was performed using an enhanced chemiluminescence kit from NEN Life Science Products (Boston, MA).
Affinity cross-linking, competitive affinity cross-linking
Purified FLAG-tagged rhIGFBP-rP3 protein (0 -200 pmol) was incubated overnight at 4 C in the presence of 125 I-labeled IGF-I, IGF-II, insulin or C-peptide (100,000 cpm) in the presence or absence of unlabeled peptides at the concentrations indicated in the text and figures. After cross-linking with disuccinimidyl suberate (0.6 mm) for 10 min at 4 C, samples were subjected to SDS-PAGE, dried, and exposed to Biomax film (Kodak, Rochester, NY) at Ϫ70 C (14) . Based upon the results obtained with affinity cross-linking studies, competitive affinity crosslinking studies were performed using 20 pmol IGFBP-rP3. Bands were quantified by densitometry with Multi-Analyst software (Bio-Rad, Hercules, CA), using the area under the curve, as calculated by a Bio-Rad densitometer (Hercules, CA).
Western ligand blotting (WLB)
Unreduced samples of FLAG-tagged rhIGFBP-rP3 and IGFBP-3 E.coli were electrophoresed on nondenaturing 12% SDS-PAGE stacking gels (pH 7.4) and resolving gels (pH 8.8) (9), and electroblotted onto nitrocellulose membranes. Membranes, upon which WIB had been performed, were stripped with TBS-T containing 3% NP-40 for 15 min, two times, before the following steps. The membranes were blocked with TBS-T containing 1% BSA at room temperature for 2 h, and then incubated overnight with 1.0 ϫ 10 6 cpm of both 125 I-labeled IGF-I and IGF-II. The membranes were then washed three times in TBS with 0.1% Tween 20 for 15 min, dried, and exposed to Biomax film at Ϫ70 C.
Antibody production
Generation of polyclonal anti-rhIGFBP-rP3 antibody was performed by immunization of three female white New Zealand rabbits with purified baculovirus generated rhIGFBP-rP3. Preimmune serum was collected before immunization. IGFBP-rP3 (100 g) in Hepes buffered saline with equal volume of Freund's complete adjuvant was administered sc at initial immunization, and two booster immunizations of IGFBP-rP3 (50 g) with equal volume of Freund's incomplete adjuvant were administered sc at one-month intervals. After the second boost, all three rabbits (B1, B2, and B3) were bled; two were exsanguinated and sera collected from total blood. The sera from rabbit B1 was used in all subsequent experiments. WIB with anti-rhIGFBP-rP3 (B1) at a 1:2000 dilution was performed as described above, except that horseradish peroxidase-linked anti-rabbit IgG (Amersham, Arlington Heights, IL) at a 1:3000 dilution was employed as the secondary antibody. Comparison studies were made with antibodies previously generated against IGFBPrP1 and -rP2 (11, 15) .
Cell culture and preparation of conditioned media
Hs578T and MCF-7 (human breast cancer cell lines) PC3, DU145, LNCAP (prostatic cell lines) were obtained from ATCC (Manassas, VA); while M12 and P69 (prostatic cell lines) were generously provided by Dr. S. R. Plymate (Tacoma, WA) (16, 17) . Cells were grown in DMEM plus 10% FCS at 37 C in 5% CO 2 , until 80% confluent and then cultured for 12 h in serum-free DMEM. Serum-free conditioned media (CM) were collected and centrifuged at 1000 ϫ g for 10 min to remove cell debris. Conditioned media from Epi110 (human normal prostate epithelial cell line) were generously provided by Dr. S. R. Plymate (Tacoma, WA). The harvested CM from triplicate wells within each experiment were pooled and stored at 70 C until evaluated by WIB, as described above, but using the anti-rhIGFBP-rP3 antibody.
Northern blot analysis of IGFBP-rP3 mRNA expression
Blots with 2 g poly(A)ϩ RNA from normal human tissues that had been subjected to electrophoresis in 1.5% formaldehyde-agarose gel before transfer to nylon membranes, were purchased from CLONTECH. 32 P-labeled cDNA probes for novH were hybridized to the blots overnight at 65 C, and washed at high stringency as previously described (18) .
Results

Construction and expression of FLAG epitopetagged rhIGFBP-rP3
Recombinant human IGFBP-rP3 was synthesized in the baculovirus expression system. The immunoblot of the fractions collected during purification of FLAG-tagged rhIGFBPrP3 on a 12% SDS-PAGE (Fig. 1A) identified an anti-M2 antibody-specific protein of 38 kDa, which is compatible with that predicted from the genetic sequence (2) . An additional band observed at approximately 28 kDa is presumed to be a COOH-terminal fragment. Application of various amounts of the purified rhIGFBP-rP3 protein on a 12% SDS-PAGE and subsequent silver staining showed that the protein had approximately 99% purity and a molecular weight of approximately 38,000 daltons. N-terminal sequencing identified the start site of the synthesized protein at amino acid 32 (TQR CPP 1 ⁄4.) (Fig. 1B , cleavage site indicated with an arrow). This site lies two amino acids downstream from that previously predicted according to the cDNA (2).
Characterization of rhIGFBP-rP3 binding properties
The IGFBPs of rhIGFBP-rP3 were investigated by the use of affinity cross-linking, competitive affinity cross-linking, and WLB studies. Binding of rhIGFBP-rP3 to IGF-I, IGF-II, and also insulin was evident on affinity cross-linking studies (Fig. 2) . Figure 2C illustrates that, while IGFBP-rP3 binds to IGF-I, IGF-II, and insulin, it does not bind to the C-peptide portion of insulin. Specificity of binding was also confirmed by competition with increasing concentrations of unlabeled peptide, in which 50% displacement of IGFBP-rP3 binding was observed with between 1000 -2000 ng/mL of IGF-I, and between 300-1000 ng/mL of IGF-II, both several orders of magnitude lower than that for IGFBP-3 (Fig. 3, A and B) . WLB studies, when performed under nondenaturing conditions, demonstrated rhIGFBP-rP3 binding to radiolabeled IGF-I and -II, although again with a much lower affinity than observed with IGFBP-rP3 (Fig. 4) ; IGFBP-rP3 binding to radiolabeled IGF-I and -II was abolished, however, by standard denaturing WLB conditions (data not shown). By these methodologies, it was evident that the affinity of rhIGFBP-rP3 for IGF-I and IGF-II was several orders of magnitude lower than the affinity of IGFBP-3 for these peptides. Binding of rhIGFBP-rP3 to insulin was observed in cross-linking, but not in WLB studies.
Characterization of anti-rhIGFBP-rP3 antibody
Characterization studies of anti-rhIGFBP-rP3 antibody confirmed detection of the baculovirus generated IGFBP-rP3 protein (38 kDa) in WLB studies (Fig. 5) . Several bands of higher molecular weight were also detected by the antibody, suggesting oligomerization of the IGFBP-rP3 protein. Disaggregation of the oligomers, with disappearance of these higher molecular weight bands, was observed when the WIB studies were performed under reducing conditions, with 100 mm dithiothreitol. The anti-IGFBP-rP3 antibody also detected IGFBP-rP3 in aliquots of serum-free Hs578T CM. The IGFBP-rP3 detected in the Hs578T CM was slightly larger than that synthesized in the baculovirus system; the observed doublet of 47 and 49 kDa is consistent with differential glycosylation of IGFBP-rP3 in mammalian cells. The anti-IGFBP-rP3 antibody showed no cross-reactivity with any of the IGFBPs -1 to -6, nor with IGFBP-rP1 and -rP2 when examined in equimol amounts (Fig. 6) . In WIBs performed with ten times the amount of IGFBP-rP1 and -rP2, compared with IGFBP-rP3, minimal cross-reactivity of the anti-IGFBPrP3 protein with IGFBP-rP1 and -rP2 was evident (data not shown). This phenomenon was attributed to antibody recognition of the FLAG epitope (DYKDDDDK), which was present in all three proteins generated in the baculovirus system (11) . Figure 6C illustrates specificity of each of the anti-IGFBP-rP antibodies, for the specific IGFBP-rP against which the antibody had been raised, in WIB experiments with equal amounts (20 ng) of IGFBP-rPs 1, 2, and 3.
Secretion of IGFBP-rP3 protein
WIB studies were performed with anti-IGFBP-rP3 antibody to investigate protein distribution in vitro (Fig. 7) and in vivo (Fig. 8) . IGFBP-rP3 was detected in conditioned media of several cell lines by WIB using anti-IGFBP-rP3 (Fig. 7) . Significant expression of IGFBP-rP3 was evident in the CM of Hs578T cells (human breast cancer cell line, estrogen receptor negative), PC3 cells (human prostate carcinoma cell IGFBP-rP3 was detected in several human biological samples by WIB studies performed using anti-IGFBP-rP3 antibody (Fig. 8) . The IGFBP-rP3 detected in these samples was larger (47 kDa) than the baculovirus expressed protein (38 kDa), consistent with post-translational glycosylation. The presence of a doublet was evident in cerebrospinal fluid (CSF) (approximately 47 kDa and 48 kDa), and an additional band (approximately 49 kDa) in the serum from patients with growth hormone receptor deficiency is also consistent with alternative forms of post-translational glycosylation. IGFBPrP3 was detected by WIB in normal human serum, human pregnancy serum, and serum from patients with growth hormone receptor deficiency, CSF, amniotic fluid, peritoneal fluid, and follicular fluid. Deglycosylation with Endo F, followed by immunoblotting, of baculovirus protein, CSF, and Hs578T-conditioned media all resulted in a decrease in the apparent M r of IGFBP-rP3 to 34.5 kD. Lower molecular weight bands (32 kDa and 28 kDa) were identified in CSF, amniotic fluid, urine from prepubertal patients, and urine from pubertal patients. This size is similar to that seen during baculovirus generation of IGFBP-rP3, suggestive of the presence of IGFBP-rP3 fragments in urine, CSF, and amniotic fluid.
Expression of IGFBP-rP3 mRNA in human tissues
The distribution of IGFBP-rP3 in normal human tissues was investigated using Northern blot analysis. As shown in Fig. 9, 2 .4 kb IGFBP-rP3 mRNA was detected in a broad range of normal human tissues. In particular, high levels of IGFBPrP3 mRNA expression were detected in prostate, testes, heart, brain, and pancreas, while IGFBP-rP3 mRNA was expressed in low levels in spleen, ovary, small intestine, colon, peripheral blood leukocytes, lung, skeletal muscle, and kidney. IGFBP-rP3 mRNA expression was not detected in thymus, placenta, or liver.
Discussion
The nov gene was first described in myeloblastosis-associated virus-induced nephroblastoma (1) and subsequently reported to be expressed in many Wilm's tumors (2) . Further interest in the NovH protein was stimulated by structural analysis of the predicted amino acid sequence (2) , which demonstrated a similarity of 46% to connective tissue growth factor (CTGF) and Cyr61, leading Bork (4) to propose the entity of the CCN family, members of which are postulated to be involved in regulation of cellular proliferation. All three members of the CCN family exhibit a modular architecture, comprising four protein domains: 1), an IGFBP-like domain; 2), the von Willebrand factor type C repeat (oligomerization domain); 3), thrombospondin type 1 repeat (cell attachment domain); and 4), a COOH-terminal module (may be involved in dimerization or receptor binding) (4) .
It has also been recognized that the N-terminal domains of these CCN proteins possess a significant degree of similarity (46%) with the N-terminal domains of the IGFBPs (4, 19) . Northern blot analysis of IGFBP-rP3 mRNA expression in normal human tissues. IGFBP-rP3 mRNA expression human normal multitissue blots were probed with IGFBP-rP3 cDNA and exposed to Biomax film for 1 day at -70 C. Lanes 1-16 are: 1, spleen; 2, thymus; 3, prostate; 4, testes; 5, ovary; 6, small intestine; 7, colon; 8, peripheral blood leukocytes; 9, heart; 10, brain; 11, placenta; 12, lung; 13, liver; 14, skeletal muscle; 15, kidney; and 16, pancreas.
Eleven of the 12 cysteines occurring in the N-terminal domain of the IGFBPs are also present in the CCN protein N-terminal domains. Additionally, the CCN proteins show conservation of the "GCGCCXXC" motif in the N-terminal domain, although the significance of this domain remains unknown. CTGF has already been demonstrated to display IGF binding (9) . The low affinity nature of the IGF binding displayed by CTGF, compared to that shown by the traditional IGFBPs, led to the proposal that such proteins should be classified separately as IGFBP-related proteins (IGFBPrPs), with recognition of an IGFBP Superfamily, comprised of high affinity IGF binders (IGFBPs -1 to -6) and low affinity IGF binders (IGFBP-rPs) (7) . In addition to IGFBP-rP3/ NovH, the IGFBP-rPs for which IGF binding has been demonstrated include mac25 (here referred to as IGFBP-rP1) (8) and CTGF (here referred to as IGFBP-rP2) (9) (Fig. 10) .
In this present study, we demonstrate that IGFBP-rP3/ NovH possesses low affinity IGF binding, as shown by both WLB, after nondenaturing PAGE, and by affinity crosslinking studies. Low affinity binding to insulin was also demonstrated for IGFBP-rP3/NovH, which is similar to IGFBP-rP1 (8) . For IGF-I, IGF-II, and insulin, the specificity of binding was demonstrated by the failure of IGFBP-rP3 to bind iodinated structurally unrelated insulin C-peptide. Furthermore, the specificity of IGFBP-rP3/NovH binding was illustrated by the dose-dependent inhibition of binding by unlabeled IGF-I or IGF-II in competitive affinity cross-linking studies. The specificity of binding, supported by the structural similarities to the IGFBPs, supports the proposal that this protein may appropriately be termed IGFBP-rP3. The IGF binding characteristics of the remaining member of the CCN family, Cyr61, have not been studied to date. Nevertheless, in view of the structural similarity with the IGFBPs, and also the IGF binding now demonstrated for the other two members of the CCN family, it would appear reasonable to consider Cyr61 as the provisional IGFBP-rP4.
The affinity of IGFBP-rP3 for IGFs, as assessed by nondenaturing western ligand blots and competitive affinity crosslinking, was estimated to be at least 100-fold lower than the IGF binding affinity of IGFBP-3. The absence of demonstrable IGF binding by IGFBP-rP3 in standard denaturing gels would suggest that secondary and tertiary structure are essential for binding. The finding that IGFBP-rP3 is a low affinity IGF binder is consistent with a similar degree of IGF binding shown by IGFBP-rP1 (8) and IGFBP-rP2 (9) . These studies on IGFBP-rP3 further support the concept that the IGFBP Superfamily may be divided into two groups: 1), IGFBPs (high affinity IGF binders), acting generally through IGF-dependent mechanisms, but with potential IGF-independent actions, as observed with IGFBP-3 (14, 20, 21) ; and 2), IGFBP-rPs (low affinity IGF binders). The high degree of similarity between the IGFBP-rPs and the IGFBPs is limited to the N-terminal domain, which apparently contains an IGF binding site (22); consequently, the IGFBP-rPs had been proposed to have potential IGF binding capacity. The lower affinity of IGFBP-rPs, compared to the IGFBPs, for IGFs may reflect the lack of significant similarity in their C-terminal domains, with consequent differences in structural configuration and an alteration in binding capacity. In addition it has been suggested that the C-terminus of the IGFBPs may have intrinsic IGF binding capacity (23) . The low affinity for the IGFs suggests that IGFBP-rPs are not likely to function as major carrier proteins or modulators of IGF action. The findings that IGFBP-rP2 (CTGF) appears to interact with specific cell surface receptor molecules (24) and that Cyr61 (provisional IGFBP-rP4) associates with the extracellular matrix and cell surface (25) both suggest that IGFBP-rP3 may well act at the level of the cell surface, possibly as a direct modulator of cell proliferation. However, much remains to be determined regarding the precise mechanisms of action of the IGFBP-rPs.
Anti-IGFBP-rP3 antibody detection of IGFBP-rP3, showing doublet bands of different molecular weights in several of the cell lines and human biological fluids, is consistent with a recent report that IGFBP-rP3 is a secreted protein, containing two glycosylation sites, and is subject to alternative forms of post-translational glycosylation (26) . The different modes of glycosylation of the IGFBP-rP3 protein could potentially alter IGFBP-rP3 interaction with extracellular matrix or other cell surface molecules, which may be involved in the mechanism of action of IGFBP-rP3, as suggested by the closely related IGFBP-rP1 and -rP2 (24, 27) .
The presence of IGFBP-rP3 mRNA in many Wilm's tumor specimens, especially the noted inverse correlation between the levels of IGFBP-rP3 mRNA and those of the tumor suppressor gene WT1, suggests a role in abnormal cell proliferation, consistent with novH as a putative protooncogene (2) . This potential involvement of IGFBP-rP3 in malignant cell growth is relevant when reviewing in vitro IGFBP-rP3 secretion by certain malignancy-derived cell lines. We have demonstrated IGFBP-rP3 protein secretion by three malignancy-derived cell lines (Hs578T, PC3, and LNCaP), shown by our WIB studies of serum-free CM. It is, however, difficult to propose a correlation between malignancy types, based upon the findings in this relatively small number of cell lines. Additional studies will be valuable to further investigate the distribution of IGFBP-rP3 in a variety of malignancies.
Our WIB studies provide interesting data on the presence and distribution of IGFBP-rP3 in human biological fluids. We showed that IGFBP-rP3 protein is present in normal adult serum. While IGFBP-rP3 fragments were detected in several types of biological fluids, it is noteworthy that the intact protein alone was evident in human pregnancy serum, a condition in which proteolysis of IGFBPs has been reported (28, 29) . The additional finding of IGFBP-rP3 protein in the serum from patients with growth hormone receptor mutations suggests that regulation of this protein does not occur via growth hormone. Fragments of IGFBP-rP3 were initially noted during our baculovirus production of IGFBP-rP3, and it is interesting to observe IGFBP-rP3 fragments in several human biological fluids, notably cerebrospinal fluid, amniotic fluid, and urine, suggestive that the IGFBP-rP3 protein may be subject to in vivo proteolysis. The significance of the wide distribution of IGFBP-rP3 in a variety of human biological fluids is difficult to determine at present, particularly as a precise biological function of IGFBP-rP3 remains to be established.
Our documentation of IGFBP-rP3 in human biological fluids is supplemented by the demonstration of IGFBP-rP3 mRNA expression in a number of human tissues. Heart, brain, prostate, testes, and pancreas showed abundant IGFBP-rP3 mRNA expression, of which only brain and heart have been previously examined (1) . In this earlier report, Joliot and colleagues detected IGFBP-rP3 mRNA expression in brain, although only in embryonic, but not adult, heart (1). However, that study examined total RNA, while we analyzed polyA RNA, and this disparity may, consequently, indicate that IGFBP-rP3 mRNA expression in the heart decreases to very low levels in adulthood. Previous studies have shown IGFBP-rP3 mRNA expression in the developing kidney and in many Wilm's tumors, whereas IGFBP-rP3 mRNA expression was, reportedly, not detected in normal adult kidney (1, 2, 26) . We report, however, detection of IGFBP-rP3 mRNA in adult kidney, suggesting that IGFBPrP3 mRNA expression continues in the adult kidney, albeit at low levels. Previous reports on the presence of IGFBP-rP3 in nonrenal tissues is limited, although IGFBP-rP3 has been reported in nervous system, muscle, cartilage, and bone (26) . Our studies detected low levels of IGFBP-rP3 mRNA expression in many additional tissues, such as spleen, ovary, small intestine, colon, peripheral blood leukocytes, lung, skeletal muscle, and kidney. These findings show that IGFBP-rP3 is widely distributed in human tissues, consistent with the hypothesis that IGFBP-rP3 may be involved in cell growth regulation.
In conclusion, recent studies from our laboratory have shown that two recent additions to the IGFBP Superfamily, namely IGFBP-rP1 (mac25/TAF/PSF) and IGFBP-rP2 (CTGF) (8, 9, 11), were low affinity IGF binders. These studies for IGFBP-rP3 also demonstrate low affinity binding for IGF-I, IGF-II, and additionally, insulin, and warrant designation of this protein as IGFBP-rP3. We have demonstrated that IGFBP-rP3 is a far more ubiquitous protein than previously appreciated, both at the mRNA and protein levels. This suggests that IGFBP-rP3, initially reported as an oncogene, could potentially be involved in malignancies other than Wilm's tumor and also in the regulation of cell growth in nonmalignant tissues.
